Susvimo Approval for Diabetic Macular Edema
Key Questions
What is Susvimo?
Susvimo is an FDA-approved eye implant for diabetic macular edema (DME). It delivers continuous anti-VEGF therapy, reducing the need for frequent injections.
What is Susvimo approved for?
Susvimo is cleared by the FDA for DME treatment. It maintains vision while shifting the paradigm for non-responders and reducing treatment burden.
How does Susvimo's dosing compare to standard treatments?
Susvimo requires refills twice yearly, compared to monthly anti-VEGF injections. This cuts monthly eye injections significantly for DME patients.
What are the benefits of Susvimo for DME patients?
Susvimo reduces injection frequency to twice yearly while maintaining vision. It offers relief for patients burdened by frequent anti-VEGF shots, especially non-responders.
How does Susvimo impact DME management?
Susvimo represents an emerging therapy beyond standard anti-VEGF injections for DME. It addresses issues like treatment non-response and recurrence through sustained delivery.
FDA approval for Susvimo implant in DME enables 2 refills/year vs monthly injections, shifting paradigm for high-burden patients.